TOKYO, May 12 (Pulse News Wire) – Renascience Inc. (4889.T) launched a Phase II clinical trial targeting advanced pancreatic cancer patients with its PAI-1 inhibitor RS-5614.
The study began on May 12, 2026 with the enrollment of the first patient at multiple sites, including Tohoku University Hospital, Kanagawa Cancer Center, and National Cancer Center Central Hospital. The trial aims to evaluate the efficacy and safety of combining RS-5614 with gemcitabine, the current standard treatment, in 50 patients with unresectable or recurrent pancreatic cancer with distant metastasis. The primary objective is to determine whether adding RS-5614 to gemcitabine improves outcomes beyond the existing standard therapy.
Key evaluation metrics include overall response rate, overall survival, progression-free survival, and disease control rate. The trial will run from May 2026 to December 2029, with a planned recruitment period of 24 months followed by a 12-month observation phase. Costs associated with the trial will be incorporated into Renascience's fiscal year 2027 earnings forecast.
RS-5614 was developed jointly by Tohoku University and Renascience and has shown promise in inhibiting tumor-associated macrophages and cancer-associated fibroblasts while enhancing immune responses against cancer cells.
🟡 Confidence: Standard AI-translated content.